Search | Clinical Trials Finder

Conditions: Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Varying needle size with intravitreal ranibizumab or aflibercept; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Central Retinal Vein Occlusion
Interventions: fluocinolone acetonide (Retisert Implant, Bausch and Lomb); Device
Lead sponsor: Glenn Jaffe; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: SCD411 0.05mL (2mg); Drug
Lead sponsor: Sam Chun Dang Pharm. Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more

Conditions: Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions: Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%; Drug · Procedure
Lead sponsor: Harrow Inc; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Retinal Vein Occlusion
Interventions: ranibizumab, Peripheral Laser; Drug · Other
Lead sponsor: Peter A Campochiaro, MD; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions: Faricimab, Port Delivery System with Ranibizumab; Drug · Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more

Conditions: Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions: Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: KSI-301; Drug
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 21 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more

Conditions: Macular Edema
Interventions: AR-1105-CF1, AR-1105-CF2; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more

Conditions: Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions: anecortave acetate; Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Intraocular Inflammation, Suspected Endophthalmitis
Interventions: Non Applicable; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 155,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: bevacizumab; Biological
Lead sponsor: Outlook Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Tucson, Arizona • Beverly Hills, California • Glendale, California + 17 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Retinal Vein Occlusion
Interventions: Nicotinic acid, Prednisolone acetate; Drug
Lead sponsor: Palo Alto Medical Foundation; Other
Eligibility: Not listed
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Retinal Vein Occlusion (RVO), Macular Edema
Interventions: Ozurdex implant; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions: Episcleral Dexamethasone; Drug
Lead sponsor: Targeted Therapy Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Retinal Vein Occlusion
Interventions: Minocycline, Placebo, Bevacizumab; Drug · Other
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Vein Occlusion
Interventions: pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 35
States / cities: Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Macular Edema, Macular Degeneration
Interventions: RHMS-RTM, SD-OCT; Device · Diagnostic Test
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions: Phase variance optical coherence tomography (PV-OCT); Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: VEGF Trap-Eye 2.0mg, Sham; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: Anti-VEGF; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Ranibizumab, Peripheral Laser; Drug · Procedure
Lead sponsor: Retina Associates of Florida, P.A.; Other
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

30g vs 33g Needle for Intravitreal Injections

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Minocycline to Treat Branch Retinal Vein Occlusion

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Study Evaluating Retinal Health Monitoring System Thickness Module

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study